WXIBF (WuXi Biologics (Cayman)) Marketable Securities: $926 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WXIBF WuXi Biologics (Cayman) Inc WXIBF
97 GF Score
Price $4.60
GF Value $5.17
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) Marketable Securities?

WuXi Biologics (Cayman) WXIBF 97 Marketable Securities is $926 Mil as of Dec. 2025. GuruFocus rates WXIBF with a GF Score™ of 97/100 and a GF Value™ of $5.17 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. WuXi Biologics (Cayman)'s Marketable Securities for the quarter that ended in Dec. 2025 was $926 Mil.

WuXi Biologics (Cayman)'s annual Marketable Securities increased from Dec. 2023 ($220 Mil) to Dec. 2024 ($334 Mil) and increased from Dec. 2024 ($334 Mil) to Dec. 2025 ($926 Mil).

WuXi Biologics (Cayman)  (OTCPK:WXIBF) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

WuXi Biologics (Cayman) Marketable Securities Related Terms

WuXi Biologics (Cayman) Marketable Securities Historical Data

* Premium members only.

The historical data trend for WuXi Biologics (Cayman)'s Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi Biologics (Cayman) Marketable Securities Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 333.35 332.65 220.39 333.84 925.57

WuXi Biologics (Cayman) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 220.39 51.71 333.84 571.08 925.57
WXIBF
97GF Score
WuXi Biologics (Cayman) Inc WXIBF
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WuXi Biologics (Cayman) Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $926 Mil mean?
WuXi Biologics (Cayman) (WXIBF) has a Marketable Securities of $926 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on WuXi Biologics (Cayman) and its competitors.
Is WuXi Biologics (Cayman)'s Marketable Securities too high?
WuXi Biologics (Cayman)'s current Marketable Securities is $926 Mil. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Marketable Securities compare to VRTX and REGN?
WuXi Biologics (Cayman)'s Marketable Securities of $926 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current Marketable Securities is $926 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.17, compared to a current price of $4.60 — trading 11% below its estimated fair value. The current Marketable Securities is $926 Mil. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Marketable Securities is $926 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued. The current stock price of $4.60 is trading 11% below its estimated GF Value™ of $5.17. GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.

Key valuation signals for WXIBF:

  • Marketable Securities: $926 Mil
  • GF Value™: $5.17 vs. price of $4.60 (11% below fair value)
  • GF Score™: 97/100 with 3 warning signs

No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score

Get the complete analysis for WXIBF

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.60
Price
$5.17
GF Value